HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 21, No 09, September 2017 – Infectious Diseases       » Breakthrough in pig-to-human organ transplant       » Silk-based wearable body sensors developed by Tsinghua researchers       » First AI-assisted treatment center in Hefei city       » Breakthrough immunotherapy for Chronic Hepatitis B virus infection       » First in Asia - Launch of multi-centre lung cancer research platform       » NUS establishes additive manufacturing facilities for biomedical applications      
BIOBOARD - AUSTRALIA
Hatchtech mechanism of action data and safety study published
Specialty pharmaceutical company Hatchtech Pte Ltd has published data describing the mechanism of action of the active ingredient (Ha44) in its lead product DeOvo™, a single application topical treatment for head lice.

The research data, published in the journal PLOS ONE describes the ability of Ha44 to fatally disrupt all stages of the life cycle of the model organism Drosophila melanogaster, from eggs to adult flies. Ha44, a small heterocyclic organic molecule, is able to chelate heavy metal ions including zinc, iron and copper and thereby disrupt metal dependent targets within the insect that require these ions for normal function.

”This research conducted under an ARC Linkage Grant in conjunction with The University of Melbourne is consistent with the spectrum of activity of Ha44 that we have observed against head lice in the laboratory and in clinical studies. It demonstrates all stages from eggs to adults are susceptible to the compound with a single application,” said Dr Vern Bowles, Hatchtech's Chief Scientific Officer. ”Furthermore the results indicate that Ha44 is acting on several targets within the insect which suggests that target site resistance is unlikely to evolve.”

The company also announced that it had successfully completed a Thorough QT (TQT) study, a clinical safety assessment required by US and European regulators for nearly all new molecular entities. Dr Lewis Schulz, Hatchtech's chief operating officer said, “We are very pleased with the results of the TQT study which provide further data supporting the safety profile of DeOvo."

Click here for the complete issue.

NEWS CRUNCH  
news Singapore leads the world in progress toward the health Sustainable Development Goals (SDGs)
news HIMSS AsiaPac17 conference and exhibition returns to address Asia's health IT challenges
news Vitafoods Asia 2017: Meeting the region's nutraceutical needs
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Healthcare Focus: LUNGS
February:
War on CANCER
March:
Get to Know TCM
April:
Diabetes: The Big Picture
May:
The Piece of Your Mind - Brain Health/Science
June:
Advocacies in Support of Rare Disease Patients
July:
Food Science & Technology
August:
Eye – the Window to your Soul
September:
Infectious Diseases
October:
No. 1 Killer — Heart Diseases
November:
Diseases threatening our Children
December:
Skin Diseases/Allergic Reactions
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2017 World Scientific Publishing Co Pte Ltd  •  Privacy Policy